The pharmaceutical industry is facing big changes driven by healthcare reform. With the move to value-based care, growing numbers of private insurers are tying medication reimbursements to care outcomes. Payers are increasingly interested in entering into risk-sharing agreements with pharmaceutical companies, which can reduce the cost of new therapeutics while strongly incentivizing pharma to monitor and invest in patient welfare.
Raising the stakes, tech giants are disrupting the market with innovative digital platforms while patients are engaging with considerably more choices than ever before. How will life sciences companies deliver personalized services, solutions and experiences? Learn what patient centricity means for life sciences companies and how to achieve it with: